Interactions between Cytokines and Drugs in COVID-19 Potential Interactions between Increased Cytokines in COVID-19 and Drugs used to Treat COVID-19
Authors:
- Tülün ÖztürkTÖTülün Öztürk
- Tuğba ÇavuşoğluTÇTuğba Çavuşoğlu
- Canet İnCirCICanet İnCir
- Yeşim TunçokYTYeşim Tunçok
- Canet İnci̇r BalabanCBCanet İnci̇r Balaban
- 31 March 2021
- journal article
- review article
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (1) , 174-185
Abstract
During COVID-19 infection, virus and host cell interactions lead to the acute production of very strong immune mediators. The clinical status caused by damage throughout the body is mostly due to excessive pro-inflammatory cytokine production from virus-induced macrophages and granulocytes. Under infectious and inflammatory conditions, clinical and experimental studies have demonstrated that hepatic and extrahepatic cytochrome P450 (CYP) enzymes and carrier proteins responsible for drug metabolism are specifically regulated by many cytokines. Downregulation of these enzymes by cytokines can cause an elevation in plasma drug levels and/or lead to adverse drug reactions and/or toxicity. Based on the knowledge of cytokine-drug interactions occurring in the infection and inflammation stage, the aim of this review was to ascertain the influence of uncontrolled cytokine release on the metabolism of drugs used alone or in combination to treat COVID-19 patients and predict drug-drug interactions causing adverse effects.Keywords
This publication has 80 references indexed in Scilit:
- Interleukin-18 and IL-18 Binding ProteinFrontiers in Immunology, 2013
- Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte CultureDrug Metabolism and Disposition, 2011
- Drug−disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activityBritish Journal of Clinical Pharmacology, 2011
- CYP-Mediated Therapeutic Protein-Drug InteractionsClinical Pharmacokinetics, 2010
- Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in miceBiochemical Pharmacology, 2010
- Regulation of P-Glycoprotein in Renal Proximal Tubule Epithelial Cells by LPS and TNF-αJournal of Biomedicine and Biotechnology, 2010
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human HepatocytesDrug Metabolism and Disposition, 2007
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Interferon γ Down–Regulates Cytochrome P450 3A Genes in Primary Cultures of Well–Differentiated Rat HepatocytesHepatology, 1996